Madhavan Balachandran has served as a member of our Board since September 2017. Mr. Balachandran served as a director of Catalent, Inc. (NYSE: CTLT) from May 2017 to January 2024. Mr. Balachandran was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Wellcome Company, a predecessor before mergers of GlaxoSmithKline plc. Mr. Balachandran holds a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo, a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology, Bombay, and an MBA from East Carolina University.
What is Madhavan Balachandran's net worth?
The estimated net worth of Madhavan Balachandran is at least $3.03 million as of June 15th, 2026. Mr. Balachandran owns 69,458 shares of uniQure stock worth more than $3,033,925 as of August 4th. This net worth estimate does not reflect any other investments that Mr. Balachandran may own. Learn More about Madhavan Balachandran's net worth.
How do I contact Madhavan Balachandran?
Has Madhavan Balachandran been buying or selling shares of uniQure?
Madhavan Balachandran has not been actively trading shares of uniQure within the last three months. Most recently, Madhavan Balachandran sold 11,685 shares of the business's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a transaction totalling $526,526.10. Following the completion of the sale, the director now directly owns 43,254 shares of the company's stock, valued at $1,949,025.24. Learn More on Madhavan Balachandran's trading history.
Who are uniQure's active insiders?
uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Rachelle Jacques (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Kylie O'Keefe (Chief Customer and Strategy Officer), Leonard Post (Director), Jeannette Potts (Insider), and Jeremy Springhorn (Director). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?
In the last twelve months, insiders at the biotechnology company sold shares 36 times. They sold a total of 829,188 shares worth more than $31,835,011.35. The most recent insider tranaction occured on July, 2nd when CEO Matthew C Kapusta sold 21,082 shares worth more than $952,063.12. Insiders at uniQure own 4.7% of the company.
Learn More about insider trades at uniQure. Information on this page was last updated on 7/2/2026.
